On May 16, professionals from the institutions that make up the HUB Alzheimer Barcelona —Ace Alzheimer Center Barcelona, Barcelonaβeta Brain Research Center (BBRC), Fundació Pasqual Maragall, Hospital Clínic Barcelona, Hospital de Sant Pau, Hospital del Mar and Hospital Universitari Vall d'Hebron— published an open letter addressed to the Ministry of Health, the Interministerial Commission on Drug Prices, and the regional health departments, calling for equitable access to new disease-modifying treatments for Alzheimer's disease.
Lecanemab and donanemab—two new disease-modifying therapies for Alzheimer's disease—have already received authorisation from the European Commission, following a positive opinion from the scientific committee of the European Medicines Agency (EMA), and are also approved by regulatory agencies such as the US FDA, the UK's MHRA, and the authorities in Japan, China, South Korea, and Israel. Despite this, Spanish patients still cannot access these therapies through the public healthcare system, while funding negotiations continue.
The signatories emphasise that the regulatory debate is already settled and that the outstanding issue is to guarantee access that is "safe, equitable, financially sustainable and clinically well organised"«. They are asking for the ongoing negotiations to be expedited, for a plan to be designed for progressive implementation in centres with accredited experience, and for investment in biomarkers, neuropsychology, magnetic resonance imaging and specialised dementia teams to be structurally reinforced, a deficit they consider to exist prior to the arrival of these drugs.
The letter also demands a a specific national Alzheimer's Plan to structure early diagnosis, professional training, care coordination and territorial equity, so that access to these treatments does not depend «on the post code or the economic capacity of each family».
With this letter, the professionals of HUB Alzheimer Barcelona make themselves available to the administrations –Ministry of Health, Interministerial Commission on Drug Prices and Health Departments– to collaborate in the design of a "responsible, progressive, evaluable and evidence-based" rollout, with the aim of continuing to care for people with Alzheimer's and their families.
The message was also sent to general and specialised media outlets, such as ConSalud.es and Infosalus, which helped disseminate it to the wider public.
You can read the full letter here.